CN109153669B - 苯甲酰胺类化合物的新晶型 - Google Patents

苯甲酰胺类化合物的新晶型 Download PDF

Info

Publication number
CN109153669B
CN109153669B CN201780031576.6A CN201780031576A CN109153669B CN 109153669 B CN109153669 B CN 109153669B CN 201780031576 A CN201780031576 A CN 201780031576A CN 109153669 B CN109153669 B CN 109153669B
Authority
CN
China
Prior art keywords
crystalline form
cancer
formula
compound
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780031576.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN109153669A (zh
Inventor
I·坎迪亚尼
G·奥塔亚诺
A·托马西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nerviano Medical Sciences SRL
Original Assignee
Nerviano Medical Sciences SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences SRL filed Critical Nerviano Medical Sciences SRL
Publication of CN109153669A publication Critical patent/CN109153669A/zh
Application granted granted Critical
Publication of CN109153669B publication Critical patent/CN109153669B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN201780031576.6A 2016-05-24 2017-05-18 苯甲酰胺类化合物的新晶型 Active CN109153669B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340797P 2016-05-24 2016-05-24
US62/340,797 2016-05-24
PCT/EP2017/061919 WO2017202674A1 (en) 2016-05-24 2017-05-18 New crystalline form of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide

Publications (2)

Publication Number Publication Date
CN109153669A CN109153669A (zh) 2019-01-04
CN109153669B true CN109153669B (zh) 2021-12-24

Family

ID=58709993

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780031576.6A Active CN109153669B (zh) 2016-05-24 2017-05-18 苯甲酰胺类化合物的新晶型

Country Status (12)

Country Link
US (2) US10738037B2 (https=)
EP (2) EP3464276B1 (https=)
JP (2) JP7094228B2 (https=)
KR (1) KR102441736B1 (https=)
CN (1) CN109153669B (https=)
AU (1) AU2017271458B2 (https=)
CA (1) CA3024208C (https=)
ES (1) ES2899953T3 (https=)
IL (1) IL263004B (https=)
MX (1) MX379558B (https=)
PL (1) PL3464276T3 (https=)
WO (1) WO2017202674A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7094228B2 (ja) 2016-05-24 2022-07-01 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｎ－［５－（３，５－ジフルオロ－ベンジル）－１ｈ－インダゾール－３－イル］－４－（４－メチル－ピペラジン－１－イル）－２－（テトラヒドロ－ピラン－４－イルアミノ）－ベンズアミドの新規結晶形
AU2020319662B2 (en) 2019-07-31 2024-02-29 F. Hoffmann-La Roche Ag New pharmaceutical formulation
WO2021084260A1 (en) * 2019-11-01 2021-05-06 Johnson Matthey Public Limited Company Crystalline entrectinib anhydrate and monohydrate forms; crystalline entrectinib thf, nitromethane, isopropyl acetate and methanol solvate forms; processes for preparing a crystalline entrectinib anhydrate form
CN113024521B (zh) * 2019-12-09 2023-01-17 武汉九州钰民医药科技有限公司 一种制备恩曲替尼的方法
CN111171009B (zh) * 2020-01-10 2022-07-12 安礼特（上海）医药科技有限公司 恩曲替尼晶型及其制备方法
CN113354626B (zh) * 2020-03-04 2025-06-03 罗欣药业(上海)有限公司 恩曲替尼的晶型及其制备方法
CN113801062B (zh) * 2020-06-15 2023-05-26 沈阳药科大学 3-氨基-5-(3,5-二氟苄基)-1h-吲唑的制备方法
CN112336723B (zh) * 2020-12-11 2023-09-26 江南大学 制备用于降低trpv4与nox2耦联度的药物的方法
US20240308990A1 (en) * 2021-02-03 2024-09-19 Qilu Pharmaceutical Co., Ltd. Crystal form of entrectinib and preparation method therefor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101754956A (zh) * 2007-07-20 2010-06-23 内尔维阿诺医学科学有限公司 作为具有激酶抑制剂活性的取代的吲唑衍生物
CN104395308A (zh) * 2012-05-23 2015-03-04 内尔维阿诺医学科学有限公司 N-[5-(3,5-二氟-苄基)-1h-吲唑-3-基]-4-(4-甲基-哌嗪-1-基)-2-(四氢-吡喃-4-基氨基)-苯甲酰胺的制备方法
WO2015124697A1 (en) * 2014-02-20 2015-08-27 Ignyta, Inc. Compounds for treating patients with ros1 mutant cancer cells

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7094228B2 (ja) 2016-05-24 2022-07-01 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｎ－［５－（３，５－ジフルオロ－ベンジル）－１ｈ－インダゾール－３－イル］－４－（４－メチル－ピペラジン－１－イル）－２－（テトラヒドロ－ピラン－４－イルアミノ）－ベンズアミドの新規結晶形

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101754956A (zh) * 2007-07-20 2010-06-23 内尔维阿诺医学科学有限公司 作为具有激酶抑制剂活性的取代的吲唑衍生物
CN103923072A (zh) * 2007-07-20 2014-07-16 内尔维阿诺医学科学有限公司 作为具有激酶抑制剂活性的取代的吲唑衍生物
CN104395308A (zh) * 2012-05-23 2015-03-04 内尔维阿诺医学科学有限公司 N-[5-(3,5-二氟-苄基)-1h-吲唑-3-基]-4-(4-甲基-哌嗪-1-基)-2-(四氢-吡喃-4-基氨基)-苯甲酰胺的制备方法
WO2015124697A1 (en) * 2014-02-20 2015-08-27 Ignyta, Inc. Compounds for treating patients with ros1 mutant cancer cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor;Maria Menichincheri，等;《Journal of Medicinal Chemistry》;20160322;第59卷(第7期);3392-3408 *

Also Published As

Publication number Publication date
PL3464276T3 (pl) 2022-04-04
AU2017271458A1 (en) 2019-01-17
WO2017202674A1 (en) 2017-11-30
US10738037B2 (en) 2020-08-11
MX379558B (es) 2025-03-11
EP3464276B1 (en) 2021-09-01
IL263004A (en) 2018-12-31
KR102441736B1 (ko) 2022-09-13
ES2899953T3 (es) 2022-03-15
JP2019516749A (ja) 2019-06-20
CA3024208A1 (en) 2017-11-30
HK1259405A1 (zh) 2019-11-29
BR112018073951A2 (pt) 2019-02-26
MX2018014298A (es) 2019-03-14
JP2021042213A (ja) 2021-03-18
IL263004B (en) 2022-04-01
EP3967689A1 (en) 2022-03-16
US20190169173A1 (en) 2019-06-06
KR20190005236A (ko) 2019-01-15
JP7154271B2 (ja) 2022-10-17
AU2017271458B2 (en) 2020-11-26
US11091469B2 (en) 2021-08-17
US20200325122A1 (en) 2020-10-15
CA3024208C (en) 2022-07-26
JP7094228B2 (ja) 2022-07-01
CN109153669A (zh) 2019-01-04
EP3464276A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
CN109153669B (zh) 苯甲酰胺类化合物的新晶型
CN104395308B (zh) N-[5-(3,5-二氟-苄基)-1h-吲唑-3-基]-4-(4-甲基-哌嗪-1-基)-2-(四氢-吡喃-4-基氨基)-苯甲酰胺的制备方法
WO2023140329A1 (ja) がんの治療または予防用医薬
CN113801139A (zh) 作为rsk抑制剂的嘧啶并恶嗪衍生物及其应用
KR102402470B1 (ko) 퀴나졸린 유도체
CN110563697A (zh) 2-吡啶甲酰胺类化合物的制备及应用
CN107151233B (zh) 含腙的嘧啶类衍生物及其用途
CN105585565A (zh) 含2-苯胺基-4-噻唑基吡啶衍生物及其制法和药物组合物与用途
CN107793363A (zh) 一种取代芳胺基芳杂环类化合物及其作为抗肿瘤药物的应用
WO2021121146A1 (zh) 氨基嘧啶类化合物甲磺酸盐的晶型a及其制备方法和应用
JP7565118B2 (ja) （ｓ，ｅ）－４－（ジメチルアミノ）－ｎ－（３－（４－（２－ヒドロキシ－１－フェネチルアミノ）－６－フェニルフロ［２，３－ｄ］ピリミジン－５－イル）フェニル）ブタ－２－エナミド遊離塩基の結晶形
CN110467616A (zh) 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用
TWI843838B (zh) 激酶抑制劑之多晶型、含有該化合物之醫藥組成物、製備方法、及應用
HK1259405B (zh) 苯甲酰胺类化合物的新晶型
BR112018073951B1 (pt) Forma cristalina de um composto de fórmula i, uso e processo para preparação da mesma e composição farmacêutica
TWI920088B (zh) Ｓｉｋ-３抑制劑及其用途
KR20250098089A (ko) 퀴나졸린 유도체 화합물의 신규한 염 및 이의 제조방법
WO2022161263A1 (zh) 新型Hedgehog信号通路抑制剂
TWI596098B (zh) 埃克替尼馬來酸鹽的晶型及其用途
HK1231856A1 (en) Benzamides, composition comprising the benzamides, and process for the preparation of the benzamides
HK1231856A (en) Benzamides, composition comprising the benzamides, and process for the preparation of the benzamides
HK1207077B (en) Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1259405

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant